Guggenheim Maintains Buy on Kymera Therapeutics, Raises Price Target to $135

Benzinga · 1d ago
Guggenheim analyst Brad Canino maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price target from $125 to $135.